Accéder au contenu
MilliporeSigma
  • Iron oxide nanoparticle-mediated development of cellular gap junction crosstalk to improve mesenchymal stem cells' therapeutic efficacy for myocardial infarction.

Iron oxide nanoparticle-mediated development of cellular gap junction crosstalk to improve mesenchymal stem cells' therapeutic efficacy for myocardial infarction.

ACS nano (2015-02-18)
Jin Han, Bokyoung Kim, Jung-Youn Shin, Seungmi Ryu, Myungkyung Noh, Jongsu Woo, Jin-Sil Park, Youjin Lee, Nohyun Lee, Taeghwan Hyeon, Donghoon Choi, Byung-Soo Kim
RÉSUMÉ

Electrophysiological phenotype development and paracrine action of mesenchymal stem cells (MSCs) are the critical factors that determine the therapeutic efficacy of MSCs for myocardial infarction (MI). In such respect, coculture of MSCs with cardiac cells has windowed a platform for cardiac priming of MSCs. Particularly, active gap junctional crosstalk of MSCs with cardiac cells in coculture has been known to play a major role in the MSC modification through coculture. Here, we report that iron oxide nanoparticles (IONPs) significantly augment the expression of connexin 43 (Cx43), a gap junction protein, of cardiomyoblasts (H9C2), which would be critical for gap junctional communication with MSCs in coculture for the generation of therapeutic potential-improved MSCs. MSCs cocultured with IONP-harboring H9C2 (cocultured MSCs: cMSCs) showed active cellular crosstalk with H9C2 and displayed significantly higher levels of electrophysiological cardiac biomarkers and a cardiac repair-favorable paracrine profile, both of which are responsible for MI repair. Accordingly, significantly improved animal survival and heart function were observed upon cMSC injection into rat MI models compared with the injection of unmodified MSCs. The present study highlights an application of IONPs in developing gap junctional crosstalk among the cells and generating cMSCs that exceeds the reparative potentials of conventional MSCs. On the basis of our finding, the potential application of IONPs can be extended in cell biology and stem cell-based therapies.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Acide oléique, technical grade, 90%
Sigma-Aldrich
Titanium(IV) chloride, ReagentPlus®, 99.9% trace metals basis
Sigma-Aldrich
Acide oléique, ≥99% (GC)
Sigma-Aldrich
Rhodamine B, ≥95% (HPLC)
Sigma-Aldrich
Acide oléique, BioReagent, suitable for cell culture
Sigma-Aldrich
Rhodamine B, for fluorescence
Sigma-Aldrich
Titanium(IV) chloride solution, 1.0 M in methylene chloride
Sigma-Aldrich
Benzyl ether, 98%
Sigma-Aldrich
Acide oléique, natural, FCC
Sigma-Aldrich
L-Lysine monohydrochloride, from non-animal source, meets EP, JP, USP testing specifications, suitable for cell culture, 98.5-101.0%
Sigma-Aldrich
Acide oléique, meets analytical specification of Ph, Eur., 65.0-88.0% (GC)
Sigma-Aldrich
Titanium(IV) chloride solution, 0.09 M in 20% HCl
Sigma-Aldrich
Calcéine AM, suitable for fluorescence, BioReagent, ≥95.0% (HPLC)
Sigma-Aldrich
L-Lysine monohydrochloride, reagent grade, ≥98% (HPLC)
Sigma-Aldrich
Titanium(IV) chloride, ≥99.995% trace metals basis
Supelco
Acide oléique, analytical standard
Sigma-Aldrich
Titanium tetrachloride, packaged for use in deposition systems
Sigma-Aldrich
Calcéine AM, Small Package (20 X 50 μg ), ≥95.0% (HPLC)
Sigma-Aldrich
Dibenzyl ether, purum, ≥98.0% (GC)
Supelco
L-Lysine monohydrochloride, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
Rhodamine B, analytical standard
Sigma-Aldrich
Calcein AM solution, 4 mM in DMSO, ≥90% (HPLC), solution
Sigma-Aldrich
L-Lysine monohydrochloride, BioUltra, ≥99.5% (AT)
Sigma-Aldrich
Benzyl ether, ≥98%, FCC, FG
Lysine hydrochloride, European Pharmacopoeia (EP) Reference Standard